Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the sale or withholding of shares to meet tax liabilities following the vesting of a 2007 Performance Share Plan (PSP) award.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions.
- Ordinary Share Sale Price: £12.08 per share (February 24, 2010).
- ADS Withholding Price: $37.42 per ADS (February 24, 2010).
Material Changes
The filing details specific reductions in shareholdings for named executives and managers to satisfy tax obligations. There are no reported material changes to the company's financial position, operations, or strategic direction in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is strictly a regulatory disclosure of insider transactions under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: All reported transactions occurred on February 24, 2010.
- Executive Directors Involved: Mr. A P Witty and Dr. M M Slaoui are identified as Executive Directors among those selling shares.
- Transaction Volume (Ordinary Shares): Total ordinary shares sold by listed individuals to meet tax liabilities included 13,851 by Mr. Witty and 17,109 by Mr. Heslop.
- Transaction Volume (ADS): Total ADSs withheld included 11,262 by Dr. Slaoui.
- Purpose: All transactions were executed solely to meet tax liabilities arising from the vesting of a Performance Share Plan award.